Qiagen NV Asset Resilience Ratio
Qiagen NV asset resilience ratio. Qiagen NV (QGEN) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Qiagen NV fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Qiagen NV (1996–2025)
Asset resilience ratio of Qiagen NV from 1996 to 2025. This chart shows how Qiagen NV's Asset Resilience Ratio has changed over time. Read Qiagen NV (QGEN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Qiagen NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Qiagen NV.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Qiagen NV maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Qiagen NV Industry Peers by Asset Resilience Ratio
Compare Qiagen NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Qiagen NV Asset Resilience Ratio by Year (1996–2025)
Qiagen NV asset resilience ratio by year from 1996 to 2025. The table below shows the annual Asset Resilience Ratio data for Qiagen NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.13% | $259.91 Million | $6.30 Billion | -4.47pp |
| 2024-12-31 | 8.60% | $489.44 Million | $5.69 Billion | +2.23pp |
| 2023-12-31 | 6.37% | $389.70 Million | $6.12 Billion | -4.56pp |
| 2022-12-31 | 10.94% | $687.60 Million | $6.29 Billion | +7.93pp |
| 2021-12-31 | 3.01% | $184.78 Million | $6.15 Billion | +1.01pp |
| 2020-12-31 | 2.00% | $117.25 Million | $5.87 Billion | -0.48pp |
| 2019-12-31 | 2.48% | $129.59 Million | $5.24 Billion | -1.61pp |
| 2018-12-31 | 4.08% | $234.61 Million | $5.75 Billion | -3.05pp |
| 2017-12-31 | 7.13% | $359.20 Million | $5.04 Billion | +4.97pp |
| 2016-12-31 | 2.16% | $93.00 Million | $4.31 Billion | -0.96pp |
| 2015-12-31 | 3.12% | $130.82 Million | $4.19 Billion | -1.01pp |
| 2014-12-31 | 4.13% | $184.04 Million | $4.45 Billion | +2.91pp |
| 2013-12-31 | 1.22% | $49.92 Million | $4.09 Billion | -0.97pp |
| 2012-12-31 | 2.19% | $90.45 Million | $4.13 Billion | +0.74pp |
| 2011-12-31 | 1.45% | $54.58 Million | $3.76 Billion | -1.26pp |
| 2010-12-31 | 2.71% | $106.08 Million | $3.91 Billion | +1.66pp |
| 2009-12-31 | 1.05% | $40.00 Million | $3.80 Billion | +0.97pp |
| 2007-12-31 | 0.08% | $2.31 Million | $2.78 Billion | -4.27pp |
| 2006-12-31 | 4.35% | $52.78 Million | $1.21 Billion | +2.39pp |
| 2005-12-31 | 1.96% | $15.00 Million | $765.30 Million | -2.26pp |
| 2004-12-31 | 4.22% | $30.15 Million | $714.60 Million | +3.04pp |
| 2003-12-31 | 1.18% | $6.53 Million | $551.93 Million | -1.35pp |
| 2002-12-31 | 2.54% | $11.53 Million | $454.51 Million | -3.77pp |
| 2001-12-31 | 6.31% | $22.51 Million | $356.97 Million | -9.88pp |
| 2000-12-31 | 16.19% | $37.27 Million | $230.26 Million | -5.43pp |
| 1999-12-31 | 21.62% | $32.02 Million | $148.12 Million | -0.69pp |
| 1998-12-31 | 22.31% | $23.80 Million | $106.70 Million | -10.39pp |
| 1997-12-31 | 32.70% | $25.80 Million | $78.90 Million | -9.75pp |
| 1996-12-31 | 42.45% | $28.10 Million | $66.20 Million | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more